Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study.

Author: Jiani WANG ¹ ; Yuwei LIU ² ; Renzhi ZHANG ³ ; Zhenyu LIU ² ; Zongbi YI ¹ ; Xiuwen GUAN ¹ ; Xinming ZHAO ³ ; Jingying JIANG ⁴ ; Jie TIAN ² ; Fei MA ¹
Author Information

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
3. Department of Diagnostic Radiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
4. School of Engineering Medicine, Beihang University, Beijing 100191, China.
Publication Type:Letter
MeSH: Humans; Female; Breast Neoplasms/pathology*; Multiomics; Trastuzumab; Receptor, ErbB-2/genetics*; Machine Learning
From: Chinese Medical Journal 2023;136(7):863-865
CountryChina
Language:English